Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
NonrulemakingNoticeFDA-2026-N-4162-0001
Comments
4
Awaiting comments
Deadline
4 days
Closes Jun 18, 2026
Net support
+100%
Support minus oppose · campaigns included
+100% excluding campaigns
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- May 22, 2026
- Comment period
- May 22, 2026 – Jun 18, 2026
- Agency
- Food and Drug Administration (FDA)
- FR Doc
- 2026-10321
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Analyzed 4 of 4 comments
100%· analysis complete
Stance breakdown
+100%
Net support
Support4
Aggregates include form-letter campaigns. Excluding them, net support is +100% across organic comments.
Who commented
Breakdown by commenter type.
Advocacy
1
Individual
3
Comments over time
Weekly arrivals, stacked by stance.
Posted May 22, 2026Deadline Jun 18, 2026
Support4Oppose0Other0
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to filter the Explorer.
Issues are identified as comment analysis progresses — nothing tagged on this document yet.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Read all 4 comments
The Explorer — every comment with stance, commenter type, and AI summaries — is part of the paid plan. $180/month per seat, 30-day money-back guarantee.